2 results match your criteria: "Memorial Sloan-Kettering Cancer Center USA.[Affiliation]"
Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer.
Int Braz J Urol
February 2019
Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
Article Synopsis
- The study examines the effectiveness of ultrasound-magnetic resonance imaging (US-MRI) fusion biopsy (FB) versus traditional transrectal ultrasound (TRUS) systematic random biopsies (SRB) in detecting prostate cancer.
- A comparison of the Gleason upgrading (GU) rates showed that TRUS SRB had higher GU rates (31.5%) compared to US-MRI FB (16.4%), indicating that US-MRI FB may provide more accurate assessments.
- The findings suggest that US-MRI FB enhances the accuracy of prostate cancer diagnosis and may lead to better treatment decisions, shown by reduced GU rates and improved concordance between biopsy results and final pathology.
Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.
Int J Mol Epidemiol Genet
July 2013
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center USA.
Tamoxifen has been shown to greatly reduce risk of recurrence and contralateral breast cancer (CBC). Still, second primary contralateral breast cancer is the most common malignancy to follow a first primary breast cancer. Genetic variants in CYP2D6 and other drug-metabolizing enzymes that alter the metabolism of tamoxifen may be associated with CBC risk in women who receive the drug.
View Article and Find Full Text PDF